Arbutus BiopharmaABUS
ABUS
About: Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. The company is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid nanoparticle technology.
Employees: 73
0
Funds holding %
of 7,359 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
69% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 13
32% more repeat investments, than reductions
Existing positions increased: 54 | Existing positions reduced: 41
25% more funds holding in top 10
Funds holding in top 10: 4 [Q3] → 5 (+1) [Q4]
6% more funds holding
Funds holding: 142 [Q3] → 151 (+9) [Q4]
1.53% more ownership
Funds ownership: 53.43% [Q3] → 54.96% (+1.53%) [Q4]
2% more call options, than puts
Call options by funds: $2.41M | Put options by funds: $2.35M
12% less capital invested
Capital invested by funds: $388M [Q3] → $340M (-$48.2M) [Q4]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$5
51%
upside
Avg. target
$5
51%
upside
High target
$5
51%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Ed Arce 43% 1-year accuracy 68 / 160 met price target | 51%upside $5 | Buy Reiterated | 21 Jan 2025 |
Financial journalist opinion
Based on 3 articles about ABUS published over the past 30 days
Neutral
GlobeNewsWire
4 days ago
Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna
BASEL, Switzerland and VANCOUVER, B.C. and WARMINSTER, Pa., March 03, 2025 (GLOBE NEWSWIRE) -- Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and a robust lipid nanoparticle (LNP) patent portfolio (a subsidiary of Roivant Sciences, Ltd. (Nasdaq: ROIV)), and Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company focused on infectious disease, today filed five international lawsuits seeking to enforce patents protecting their innovative LNP technology against Moderna, Inc. and certain affiliates. Together, the enforcement actions target alleged infringing activities in 30 countries.
Neutral
GlobeNewsWire
4 days ago
Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna
BASEL, Switzerland and VANCOUVER, British Columbia and WARMINSTER, Pa., March 03, 2025 (GLOBE NEWSWIRE) -- Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and a robust lipid nanoparticle (LNP) patent portfolio (a subsidiary of Roivant Sciences, Ltd. (Nasdaq: ROIV)), and Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company focused on infectious disease, today filed five international lawsuits seeking to enforce patents protecting their innovative LNP technology against Moderna, Inc. and certain affiliates. Together, the enforcement actions target alleged infringing activities in 30 countries.
Neutral
GlobeNewsWire
1 week ago
Arbutus Announces Changes to Board of Directors and Appointment of Lindsay Androski as CEO
WARMINSTER, Pa., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today announced changes to its board of directors and the appointment of Lindsay Androski, J.D.
Positive
Seeking Alpha
1 month ago
Arbutus, Burford Capital, And Cadiz With Chris DeMuth Jr.
Chris DeMuth, Jr. shares some of his current top picks. Arbutus Biopharma is a promising investment due to its potential litigation value from IP claims against Pfizer and Moderna related to COVID-19 vaccine technology.
Neutral
GlobeNewsWire
1 month ago
Arbutus Provides 2025 Corporate and Financial Update
Initiating Phase 2b clinical trial in first half of 2025 after achieving a meaningful functional cure rate in cHBV patients treated with imdusiran and interferon
Positive
Seeking Alpha
1 month ago
Arbutus: Positive Imdusiran Data Leads To Phase 2B Development
Company's phase 2a trial of Imdusiran with pegylated interferon alfa-2a achieved a functional cure in 25% of Hepatitis B patients. The company is developing its own in-house oral PD-L1 inhibitor, AB-101, with preliminary data expected in the first half of 2025. The global Hepatitis B Virus market size is anticipated to reach $6.65 billion by 2034.
Neutral
Business Wire
3 months ago
Whitefort Capital Sends Letter to Arbutus Biopharma Board of Directors
NEW YORK--(BUSINESS WIRE)--Whitefort Capital Management, LP (together with its affiliates, “Whitefort Capital,” “us” or “we”), which is a long-term investor and the third largest shareholder of Arbutus Biopharma Corp. (NASDAQ: ABUS) (“Arbutus” or the “Company”) with an ownership interest of approximately 6.8% of the Company's outstanding shares, today published a letter to the Company's Board of Directors (the “Board”) outlining its views on the actions Arbutus must take in order to preserve an.
Neutral
GlobeNewsWire
3 months ago
Arbutus to Participate in H.C Wainwright @ Home Virtual Fireside Chat
WARMINSTER, Pa., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that the Company will participate in the virtual H.C Wainwright @ Home fireside chat series taking place on Tuesday, December 3, 2024 at 11:00 am ET.
Neutral
GlobeNewsWire
3 months ago
Arbutus' Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon
50% of patients who had baseline HBsAg levels less than 1000 IU/mL achieved functional cure in Cohort A1 of the IM-PROVE I Phase 2a clinical trial
Neutral
GlobeNewsWire
3 months ago
Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B
Significantly greater mean declines in HBsAg levels (p
Charts implemented using Lightweight Charts™